THE INVESTOR

메뉴열기

Daewoong Pharma’s antibiotics launched in US

PUBLISHED : April 19, 2017 - 16:04

UPDATED : April 19, 2017 - 16:04

  • 본문폰트 작게
  • 본문폰트 크게
  • 페이스북
  • 트위터
  • sms

[THE INVESTOR] Daewoong Pharmaceutical said on April 19 that its generic antibiotic Meropenem has hit shelves in the US.

Meropenem, which is used in treatment for a wide range of diseases ranging from serious bacterial infection to general infection, was rolled out under the name Daewoong Meropenem Inj in the world’s largest pharma market, it said.

In December 2012, the US Food and Drug Administration accepted Daewoong Pharma’s application to sell the antibiotic, which is in reference to multinational pharmaceutical company AstraZeneca’s Merrem.

It marks the first time for a generic drug manufactured by a local drug firm to be sold in the US, company officials said.

“The company hopes the launch of Meropenem will boost the image of South Korean pharmaceutical companies in the US drug market. The company will step up efforts to bring internationally competitive products,” said Lee Jong-wook, vice president of Daewoong Pharma, in a press release.

By Alex Lee and newswires (alexlee@heraldcorp.com)

  • 페이스북
  • 트위터
  • sms
최상단으로
Herald Corporation|CEO : Kwon Chung Won
JUVENILE PROTECTION MANAGER : Shin Chang Hoon
Company Registration No. 104-81-06004
Mail-Order Business Registration 2016 - Seoul Yongsan - 00590
Huam-ro 4-gil 10, Yongsan-gu, Seoul, Korea
T : +82-2-727-0615|Business info
COPYRIGHT HERALD CORPORATION. ALL RIGHTS RESERVED.